References
Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52(5):1168–1176. doi:10.1007/s10620-006-9579-1.
Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavarin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:226–2271. doi:10.1056/NEJMoa032502.
Srivastava S, Bertagnoli M, Lewis JH. Sustained virological response rate to pegylated interferone plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a University Liver Clinic. JAMA. 2005;97:1703–1707.
Elgawly S, Khokhar OS, Lewis JH. Satisfaction with the decision to defer treatment for chronic hepatitis C declines over time: results of a 2-year follow-up questionnaire survey. Gastroenterology. 2007;132(4 suppl 2 abstract M1870):A-793–A-794.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Borum, M.L., Igiehon, E., Shafa, S. et al. African Americans May Differ in Their Reasons for Declining Hepatitis C Therapy Compared to Non-African Americans. Dig Dis Sci 54, 1604–1605 (2009). https://doi.org/10.1007/s10620-009-0806-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-009-0806-4